TY - JOUR AU - Borchert, Sabrina AU - Wessolly, Michael AU - Schmeller, Jan AU - Mairinger, Elena AU - Kollmeier, Jens AU - Hager, Thomas AU - Mairinger, Thomas AU - Herold, Thomas AU - Christoph, Daniel C. AU - Walter, Robert F. H. AU - Eberhardt, Wilfried E. E. AU - Plönes, Till AU - Wohlschlaeger, Jeremias AU - Aigner, Clemens AU - Schmid, Kurt Werner AU - Mairinger, Fabian D. PY - 2019 DA - 2019/01/30 TI - Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro JO - BMC Cancer SP - 108 VL - 19 IS - 1 AB - Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the rather poor efficacy of chemotherapeutic treatment are largely unknown. However, it is conceivable that DNA repair mechanisms lead to an impaired therapy response. We hypothesize a major role of homologous recombination (HR) for genome stability and survival of this tumour. Therefore, we analysed genes compiled under the term “BRCAness”. An inhibition of this pathway with olaparib might abrogate this effect and induce apoptosis. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-019-5314-0 DO - 10.1186/s12885-019-5314-0 ID - Borchert2019 ER -